BAFF inhibition in SLE-Is tolerance restored?

Area of Science:

• Immunology
• Rheumatology
• Molecular Biology

Background:

• Belimumab is the first approved biologic for Systemic Lupus Erythematosus (SLE).
• B cell activating factor (BAFF) and APRIL are key cytokines regulating B cell survival and differentiation.
• BAFF influences autoreactive B cell maturation and activation through various pathways.

Purpose of the Study:

• To review the mechanisms of BAFF/APRIL signaling in promoting autoreactive B cell activation.
• To discuss the role of altered selection in the therapeutic benefits of BAFF inhibition.
• To explore how BAFF/APRIL family complexity can improve human lupus treatments.

Main Methods:

• Review of existing literature on BAFF, APRIL, and their roles in SLE.
• Analysis of mechanisms underlying B cell activation and selection.
• Discussion of therapeutic implications of BAFF/APRIL inhibition.

Main Results:

• BAFF is critical for transitional and mature B cell survival, impacting autoreactive cell maturation.
• BAFF modulates innate B cell responses via B cell receptor (BCR) and Toll-like receptor (TLR) pathways.
• BAFF and APRIL support plasma cell survival, with differential effects on antibody production.

Conclusions:

• BAFF/APRIL signaling significantly promotes autoreactive B cell activation in SLE.
• Therapeutic inhibition of BAFF/APRIL can delay disease onset in murine models, but responses vary.
• Further insights into BAFF/APRIL family complexity are needed to optimize human lupus treatments.